Objective：This study aims to prepare a human anti-c-Met full-molecule antibody（c-Met-IgG1）conjugated with recombinant analgesic-antitumor peptide（rAGAP） to analyze their biological characteristics and detect their effects on the biological behavior of ovarian cancer cells. Methods：Using the human anti-c-Met antibody gene stored in our laboratory as a template，construct the c-Met-IgG1-rAGAP eukaryotic expression vector was constructed and transfected it into eukaryotic cells to obtain the antibody conjugate. The immunological properties of c-Met-IgG1 and c-Met-IgG1-rAGAP were evaluated by methods such as affinity detection，immunofluorescence，and flow cytometry. CCK-8，scratch test，and Transwell invasion test were used to detect the effects of antibodies on the proliferation，migration and invasion of ovarian cancer cells. Results：Two antibodies，c-Met-IgG1 and c-Met-IgG1-rAGAP，which can specifically bind to c-Met protein，were successfully prepared；c-Met-IgG1 and c-Met-IgG1-rAGAP proved in a series of experiments can inhibit the proliferation，migration and invasion of the c-Met-positive ovarian cancer cell HO8910，and the inhibitory effect of c-Met-IgG1-rAGAP on ovarian cancer cells is higher than that of c-Met-IgG1，while these effects were not observed in the c-Met-negative IOSE386 cells. Conclusion：The research results show that c-Met-IgG1-rAGAP can target c-Met-positive ovarian cancer cells and has anti-tumor activity，which can lay a research foundation for exploring molecular targeted treatment of ovarian cancer.